By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gentel Biosciences today announced a licensing deal with Oregon Health & Science University covering viral antigens for use on its Colony Surveillance Assays.

The deal is for worldwide commercial use, and the addition of the antigens complements Gentel's strategy to grow its product line to support translational research disease models, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.